BGM Group Ltd.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BGM Group Ltd. (Nasdaq: BGM), founded in 2019 and headquartered in Chengdu, China, operates as a pharmaceutical and chemical company through its subsidiaries, primarily manufacturing and distributing active pharmaceutical ingredients, traditional Chinese medicine derivatives, and related products in China. The company offers oxytetracycline products including Qilian Shan oxytetracycline tablets for preventing and treating diseases in chickens, turkeys, cattle, swine, and humans, and Qilian Shan oxytetracycline APIs for use in medication manufacturing; licorice products such as Gan Di Xin tablets from raw licorice, Qilian Shan licorice extract for traditional tablets, and Qilian Shan licorice liquid extract for compound oral solutions; traditional Chinese medicine derivatives like Ahan antibacterial paste for chronic skin diseases and heparin sodium preparations for cardiovascular, cerebrovascular, and hemodialysis treatments; sausage casings including Zhu Xiaochang for culinary use; and fertilizer products such as Xiongguan organic and organic-inorganic compound fertilizers to enhance crop yield and soil properties. BGM Group also focuses on AI-driven commercialization through its DuXiaoBao platform, with strategic emphasis on AI applications, intelligent robots, algorithmic computing, cloud computing, and biopharmaceuticals targeting insurance sales and pharmaceutical manufacturing. In recent developments, the company completed the acquisition of high-quality assets from AIX Inc. including RONS Technology and Xinbao Investment in late 2024, marking entry into AI technology, financial, and insurance services; acquired 100% of HM Management Company Limited (encompassing Catch Group and Expansion Group) in June 2025 via issuance of 16.6 million Class A shares to bolster AI applications; and announced further strategic acquisitions like Shuda Technology and New Media Start in May 2025 to enhance its multi-agentic AI production platform.
BGM Group Ltd. (NASDAQ:BGM) Short Interest Down 13.0% in February
BGM Group Ltd. Receives NASDAQ Notice Related to Late Filing of Form 20-F
BGM Group (NASDAQ:BGM) Stock Price Down 1% – Should You Sell?
BGM Group (NASDAQ:BGM) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM) Financial Contrast
BGM Group: I Think I Found An Undervalued Stock
BGM To Report First Half 2025 Unaudited Financial Results on July 24, 2025
What Is Behind BGM Stock's 90%+ Surge This Year
From Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts
BGM Group Announces Strategic Acquisition of HM Management to Expand AI Application Ecosystem
BGM Completes Acquisition of YX to Advance AI-Powered Intelligent Platform
BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy
BGM Acquires YX to Strengthen AI Strategy for Its Intelligent Platform
BGM Group Announces Board Reshuffle: New Leadership Embarks on a Transformative Journey Amid Tech Revolution
BGM Group Establishes "Duxiaobao Management Committee" to Accelerate AI Strategy and Drive Intelligent Transformation in the Insurance Industry
BMG Completed Acquisition of High-Quality Assets, Marking a New Chapter in Diversified Growth
In-Depth Analysis of BGM Group: Innovating Pharmaceuticals and Insurance through AI
BGM Group and Jointown Deepen Cooperation, Ushering in a New Era of Pharmaceutical Development